HC Wainwright reaffirmed their buy rating on shares of Poseida Therapeutics (NASDAQ:PSTX – Free Report) in a research note issued to investors on Monday morning, Benzinga reports. They currently have a $20.00 target price on the stock.
Poseida Therapeutics Stock Performance
NASDAQ PSTX traded up $0.13 during trading hours on Monday, hitting $2.16. The company had a trading volume of 553,519 shares, compared to its average volume of 710,663. The company has a debt-to-equity ratio of 0.56, a quick ratio of 3.18 and a current ratio of 3.18. Poseida Therapeutics has a 1-year low of $1.54 and a 1-year high of $4.27. The company has a market cap of $207.94 million, a PE ratio of -1.51 and a beta of 0.36. The business has a 50 day moving average of $3.20 and a 200-day moving average of $2.95.
Poseida Therapeutics (NASDAQ:PSTX – Get Free Report) last released its quarterly earnings data on Thursday, March 7th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.09. Poseida Therapeutics had a negative net margin of 190.76% and a negative return on equity of 94.90%. The company had revenue of $25.00 million during the quarter, compared to the consensus estimate of $12.50 million. As a group, equities research analysts expect that Poseida Therapeutics will post -1.77 EPS for the current year.
Institutional Inflows and Outflows
Several large investors have recently added to or reduced their stakes in the company. Public Employees Retirement System of Ohio acquired a new position in Poseida Therapeutics during the fourth quarter worth about $76,000. Cantor Fitzgerald L. P. acquired a new position in Poseida Therapeutics during the fourth quarter worth about $169,000. Tower Research Capital LLC TRC grew its position in Poseida Therapeutics by 110.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 10,679 shares of the company’s stock worth $36,000 after buying an additional 5,606 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in Poseida Therapeutics during the fourth quarter worth about $36,000. Finally, MCF Advisors LLC grew its position in Poseida Therapeutics by 476.4% during the fourth quarter. MCF Advisors LLC now owns 247,024 shares of the company’s stock worth $830,000 after buying an additional 204,170 shares during the period. 46.87% of the stock is owned by hedge funds and other institutional investors.
About Poseida Therapeutics
Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company’s development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.